1
Gunic Esmir, Chow Suetying, Rong Frank: Phosphoramidate prodrugs for treatment of viral infection. Valeant Research & Development, Gunic Esmir, Chow Suetying, Rong Frank, REESE Heidi L, November 16, 2006: WO/2006/121820 (68 worldwide citation)

The invention concerns 2'-methyl ribonucleotide phosphoramidates which are neutral prodrugs which are converted in vivo to 2'- methyl ribonucleotide triphosphates. These compounds are useful in the treatment of viral infection. Of particular interest are prodrugs of a methylsulfonylhydrazinyl purine ...


2
Gunic Esmir, Hong Zhi, Girardet Jean Luc: 3, 5 - cyclic nucleoside analogues for treatment of hcv. Valeant Research & Development, Gunic Esmir, Hong Zhi, Girardet Jean Luc, REESE Heidi, March 8, 2007: WO/2007/027248 (48 worldwide citation)

This invention provides compounds according to formula (I) where B is a 6-membered monocyclic nitrogen-containing heteroaryl group or a 5 + 6 fused bicyclic nitrogen-containing heteroaryl group, and A is selected from Groups (1), (2), (3), and (4) where Groups (1), (2), (3), and (4), are defined her ...


3
Zbigniew Pietrzkowski, Guangyi Wang, Johnson Lau, Zhi Hong, Jean Luc Girardet, Esmir Gunic: Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides. Valeant Research & Development, Brown Raysman Millstein Felder & Steiner, July 25, 2006: US07081449 (43 worldwide citation)

A purine nucleoside analog includes a pyrido[2,3-d]pyrimidine or a pyrimido[4,5-d]pyrimidine and further has a sugar moiety that is optionally modified at the C2′, C3′, C4′ and/or C5′ position. Particularly contemplated compounds also include prodrug forms of the purine nucleoside analogs, and both ...


4
Weijian Zhang, William Ricketts, Haoyun An, Zhi Hong: Heterocyclic compounds and uses thereof. Valeant Research & Development, Brown Raysman Millstein Felder & Steiner, January 24, 2006: US06989451 (17 worldwide citation)

Substituted isothiazole compounds and compositions are provided, wherein particularly preferred compositions and methods are directed towards inhibition of various protein kinases (especially MEK and/or ERK). Consequently, particularly preferred methods include treatment of diseases associated with ...


5
Victor Brantl: Use of ribofuranose derivatives against inflammatory bowel diseases. Valeant Research & Development, Brown Raysman Millstein Felder & Steiner, August 16, 2005: US06930093 (14 worldwide citation)

A method for the prophylaxis or treatment of an inflammatory bowel disease is provided, comprising administering to a patient having or at risk of developing an inflammatory bowel disease a therapeutically or preventatively effective amount of one or more ribofuranose derivatives having the Formula ...


6
Hong Zhi: Treatment of hcv with subtherapeutic doses of ribavirin. Valeant Research & Development, Hong Zhi, DEMERS James P, November 30, 2006: WO/2006/127289 (10 worldwide citation)

The invention provides combinations of ribavirin with other antiviral drugs, wherein what would normally be a sub-therapeutic dose of ribavirin is rendered effective by a synergistic interaction with one or more other antiviral agents. The invention also provides combinations of ribavirin with other ...


7
Zhi Hong, Yung hyo Koh, Jae Hoon Shim, Jean Luc Girardet: Antiviral phosphonate compounds and methods therefor. Valeant Research & Development, Thelen Reid Brown Raysman & Steiner, July 24, 2007: US07247621 (8 worldwide citation)

Pharmaceutical compositions comprise a nucleotide analog with a phosphonate group at a concentration effective to act as a substrate and/or inhibitor of a viral polymerase, and especially of the HCV RNA dependent RNA polymerase.


8
Robert Tam: G-rich oligo aptamers and methods of modulating an immune response. Valeant Research & Development, Brown Raysman Millstein Felder & Steiner, February 7, 2006: US06994959 (2 worldwide citation)

Aptamer oligonucleotides specifically bind to the DNA binding site of proteins such as Sp1 and Sp1-related proteins which regulate the genes which encode costimulatory molecules such as CD28 and cytokines such as IL-2 and GMCSF. The oligonucleotides compete with the DNA-binding sites of regulatory p ...


9
Chen Huanming, Raney Anneke K, Allan Matthew J, Song Jianlan, Lang Stanley A: Thiazolidinones, oxazolidinones, and pyrrolidinones for hbv. Valeant Research & Development, Chen Huanming, Raney Anneke K, Allan Matthew J, Song Jianlan, Lang Stanley A, REESE Heidi, February 1, 2007: WO/2007/014023 (2 worldwide citation)

The present invention relates to certain single-enantiomer pyrrazol-4-yl derivatives of thiazolidinones, oxazolidinones, and pyrrolidinones which are useful in the treatment of Hepatitis B virus.


10
Kanda Ramasamy, Jean Luc Girardet, Haoyun An, Zhi Hong, Robert Orr: Synthesis for hydroxyalkylated heterocyclic bases. Valeant Research & Development, Saliwanchik Lloyd & Saliwanchik, May 13, 2008: US07371857

A hydroxyalkylated heterocyclic base is prepared by reacting a heterocyclic base with an alkylene carbonate in dimethylacetamide as a solvent, wherein the hydroxyalkylated heterocyclic base is isolated from the solvent using isopropanol or tert-butylmethylether.